Recent

% | $
Quotes you view appear here for quick access.

Pharmacyclics, Inc. Message Board

  • searanch919 searanch919 Jun 4, 2012 12:09 PM Flag

    Updated Results

    powerful stuff:

    "Overall response rate in the 420 mg cohort is 81% using ibrutinib as a single agent. 12% of patients achieved a complete response with no morphologic evidence of CLL. Progression free survival with a median follow-up of 14.4 months is 96% in the 420 mg cohort."

 
PCYC
261.250.00(0.00%)May 22 4:00 PMEDT